| ○種別 (必須): | □ | 学術論文 (審査論文)
| [継承] |
| ○言語 (必須): | □ | 英語
| [継承] |
| ○招待 (推奨): |
| ○審査 (推奨): |
| ○カテゴリ (推奨): |
| ○共著種別 (推奨): |
| ○学究種別 (推奨): |
| ○組織 (推奨): |
| ○著者 (必須): | 1. | 軒原 浩
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 2. | 荻野 広和 ([徳島大学.病院.診療科.内科.呼吸器・膠原病内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 3. | 三橋 惇志 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.呼吸器・膠原病内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 4. | (英) Kondo Kensuke (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 5. | (英) Ogawa Ei (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 6. | 尾崎 領彦 ([徳島大学.病院.診療科.内科.呼吸器・膠原病内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 7. | (英) Yabuki Yohei (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 8. | 米田 浩人
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 9. | 大塚 憲司
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 10. | 西岡 安彦 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.呼吸器・膠原病内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| ○題名 (必須): | □ | (英) Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion. (日)
| [継承] |
| ○副題 (任意): |
| ○要約 (任意): | □ | (英) These data suggest the efficacy of osimertinib may differ between EGFR T790M-positive and -negative NSCLC patients with PE. (日) A total of 63 patients with EGFR mutated NSCLC were treated with osimertinib; 33 (12 with PE) had no EGFR T790M mutation, while 30 (12 with PE) had EGFR T790M mutation. In EGFR T790M-negative NSCLC, the progression-free survival (PFS) of the patients with PE was comparable to that of the patients without PE (median PFS 19.8 vs. 19.8 months, p = 0.693). In EGFR T790M- positive NSCLC, the PFS and overall survival (OS) of the patients with PE were significantly shorter than those of the patients without PE (median PFS 16.8 vs. 8.3 months, p = 0.003; median OS 44.9 vs. 14.2 months, p = 0.007). In the multivariate analysis, the presence of PE was independently associated with shorter PFS and OS in EGFR T790M-positive NSCLC patients, but not EGFR T790M-negative patients.
| [継承] |
| ○キーワード (推奨): | 1. | (英) Acrylamides (日) (読)
| [継承] |
| 2. | (英) Aniline Compounds (日) (読)
| [継承] |
| 3. | (英) Carcinoma, Non-Small-Cell Lung (日) (読)
| [継承] |
| 4. | (英) ErbB Receptors (日) (読)
| [継承] |
| 5. | (英) Humans (日) (読)
| [継承] |
| 6. | (英) Lung Neoplasms (日) (読)
| [継承] |
| 7. | (英) Mutation (日) (読)
| [継承] |
| 8. | (英) Pleural Effusion (日) (読)
| [継承] |
| 9. | (英) Protein Kinase Inhibitors (日) (読)
| [継承] |
| 10. | (英) Retrospective Studies (日) (読)
| [継承] |
| ○発行所 (推奨): |
| ○誌名 (必須): | □ | BMC Cancer ([BioMed Central Ltd.])
(eISSN: 1471-2407)
| ○ISSN (任意): | □ | 1471-2407
ISSN: 1471-2407
(eISSN: 1471-2407) Title: BMC cancerTitle(ISO): BMC CancerPublisher: BioMed Central (NLM Catalog)
(Scopus)
(CrossRef)
(Scopus information is found. [need login]) | [継承] |
| [継承] |
| ○巻 (必須): | □ | 22
| [継承] |
| ○号 (必須): | □ | 1
| [継承] |
| ○頁 (必須): | □ |
| [継承] |
| ○都市 (任意): |
| ○年月日 (必須): | □ | 西暦 2022年 6月 1日 (令和 4年 6月 1日)
| [継承] |
| ○URL (任意): |
| ○DOI (任意): | □ | 10.1186/s12885-022-09701-2 (→Scopusで検索)
| [継承] |
| ○PMID (任意): | □ | 35650550 (→Scopusで検索)
| [継承] |
| ○CRID (任意): |
| ○WOS (任意): |
| ○Scopus (任意): |
| ○評価値 (任意): |
| ○被引用数 (任意): |
| ○指導教員 (推奨): |
| ○備考 (任意): | 1. | (英) PublicationType: Journal Article (日)
| [継承] |